[
{"MaximumAge": "90", "Description": "Double-blind, placebo-controlled, crossover study investigating the effects of estrogen replacement and testosterone replacement on cognition and mood in older adults. Women who have not had a hysterectomy will be given Prempro (estrogen with progesterone to protect the uterine lining), and hysterectomized women will be given Premarin (estrogen only).", "Title": "The Effects of Sex Hormones on Cognition and Mood in Older Adults", "URL": "https://clinicaltrials.gov/show/NCT00000175", "Gender": "Both", "FileName": "NCT00000175.txt", "NCTID": "NCT00000175", "Summary": "This study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. During the nine month long study, men will take testosterone for three months and women will take estrogen for three months. At four points during the study (once every three months), participants will complete a test battery and have blood drawn.", "OrgStudyId": "IA0016", "Keywords": "['Emotions','Cognition','Aging','Memory']", "Phase": "N/A", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000175.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "HealthyVolunteers": "Accepts Healthy Volunteers", "OverallStatus": "Terminated", "MinimumAge": "65"},
{"MaximumAge": "0", "Description": "PREventing Postmenopausal memory loss and Alzheimer's with Replacement Estrogens (PREPARE) is a double-blind-placebo controlled trial to determine whether estrogen (or estrogen and progesterone) can delay the onset of memory loss or Alzheimer's Disease in elderly women with a family history of the disease.", "Title": "Alzheimer's Disease Prevention Trial", "URL": "https://clinicaltrials.gov/show/NCT00000176", "Gender": "Female", "FileName": "NCT00000176.txt", "NCTID": "NCT00000176", "Summary": "This is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.", "OrgStudyId": "IA0018", "Keywords": "['Alzheimers disease','memory loss','Estrogen']", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000176.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.", "HealthyVolunteers": "Accepts Healthy Volunteers", "OverallStatus": "Completed", "MinimumAge": "65"},
{"StartDate": "October 1995", "Title": "Estrogen Hormone Protocol", "URL": "https://clinicaltrials.gov/show/NCT00000177", "Gender": "Female", "FileName": "NCT00000177.txt", "NCTID": "NCT00000177", "Summary": "Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.", "OrgStudyId": "IA0001", "Keywords": "['Alzheimers disease','Estrogen']", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000177.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "60"},
{"MaximumAge": "0", "Title": "Multicenter Trial of Prednisone in Alzheimer's Disease", "URL": "https://clinicaltrials.gov/show/NCT00000178", "Gender": "Both", "FileName": "NCT00000178.txt", "NCTID": "NCT00000178", "Summary": "This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.", "OrgStudyId": "IA0002", "Keywords": "['Alzheimers disease','Prednisone','Anti-inflammatory agents']", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000178.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Multicenter Trial of Prednisone in Alzheimer's Disease", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MinimumAge": "0"},
{"MaximumAge": "0", "Title": "Agitation in Alzheimer's Disease", "URL": "https://clinicaltrials.gov/show/NCT00000179", "Gender": "Both", "FileName": "NCT00000179.txt", "NCTID": "NCT00000179", "Summary": "Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.", "OrgStudyId": "IA0003", "Keywords": "['Alzheimers disease','Psychomotor agitation','Behavioral symptoms','Haloperidol','Trazodone','Anti-psychotic agents','Anti-depressant agents']", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000179.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MinimumAge": "50"},
{"MaximumAge": "0", "Title": "AIT-082 Phase 1B Study", "URL": "https://clinicaltrials.gov/show/NCT00000180", "Gender": "Both", "FileName": "NCT00000180.txt", "NCTID": "NCT00000180", "Summary": "AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.", "OrgStudyId": "IA0008", "Keywords": "['Memory','Mild cognitive impairment','Nerve growth factors']", "Phase": "Phase 1", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000180.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "HealthyVolunteers": "Accepts Healthy Volunteers", "OverallStatus": "Completed", "MinimumAge": "0"},
{"StartDate": "July 1992", "Title": "Ritanserin in Treatment of Cocaine Dependence - 1", "URL": "https://clinicaltrials.gov/show/NCT00000187", "Gender": "Male", "FileName": "NCT00000187.txt", "NCTID": "NCT00000187", "Summary": "The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.", "OrgStudyId": "NIDA-00144-1", "Keywords": "['Cocaine Dependence','ritanserin']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000187.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Ritanserin in Treatment of Cocaine Dependence", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "47", "MinimumAge": "28"},
{"StartDate": "September 1994", "Title": "Selegiline in Treatment of Cocaine Dependence - 2", "URL": "https://clinicaltrials.gov/show/NCT00000188", "Gender": "Both", "FileName": "NCT00000188.txt", "NCTID": "NCT00000188", "Summary": "The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.", "OrgStudyId": "NIDA-00144-2", "Keywords": "['Cocaine Dependence','Selegiline']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000188.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Selegiline in Treatment of Cocaine Dependence", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1990", "Title": "Gepirone vs Placebo in Treatment of Cocaine Dependence - 3", "URL": "https://clinicaltrials.gov/show/NCT00000189", "Gender": "Male", "FileName": "NCT00000189.txt", "NCTID": "NCT00000189", "Summary": "The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.", "OrgStudyId": "NIDA-00144-3", "Keywords": "['Cocaine Dependence','Gepirone']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000189.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Gepirone vs Placebo in Treatment of Cocaine Dependence", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1991", "Title": "Cocaine in Parotid Saliva, Blood and Urine - 4", "URL": "https://clinicaltrials.gov/show/NCT00000190", "Gender": "Male", "FileName": "NCT00000190.txt", "NCTID": "NCT00000190", "Summary": "The purpose of this study is to establish the use of parotid saliva as a means of detecting and quantifying cocaine and its metabolites.", "OrgStudyId": "NIDA-00144-4", "Keywords": "['Cocaine Detection','Parotid Saliva']", "Phase": "Phase 1", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000190.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Cocaine in Parotid Saliva, Blood and Urine", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1991", "Title": "Carbamazepine Treatment for Cocaine Dependence - 5", "URL": "https://clinicaltrials.gov/show/NCT00000191", "Gender": "Both", "FileName": "NCT00000191.txt", "NCTID": "NCT00000191", "Summary": "The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.", "OrgStudyId": "NIDA-00144-5", "Keywords": "['Cocaine Dependence','Carbamazepine']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000191.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Carbamazepine Treatment for Cocaine Dependence", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "51", "MinimumAge": "21"},
{"StartDate": "January 1993", "Title": "Neurobiology of Opioid Dependence: 1 - 1", "URL": "https://clinicaltrials.gov/show/NCT00000192", "Gender": "Both", "FileName": "NCT00000192.txt", "NCTID": "NCT00000192", "Summary": "The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.", "OrgStudyId": "NIDA-00191-1", "Keywords": "['opioid disorders']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000192.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Neurobiology of Opioid Dependence: 1", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1993", "Title": "Neurobiology of Opioid Dependence: 2 - 2", "URL": "https://clinicaltrials.gov/show/NCT00000193", "Gender": "Male", "FileName": "NCT00000193.txt", "NCTID": "NCT00000193", "Summary": "The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.", "OrgStudyId": "NIDA-00191-2", "Keywords": "['Opioid disorders']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000193.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Neurobiology of Opioid Dependence: 2", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1993", "Title": "Neurobiology of Opioid Dependence: 3 - 3", "URL": "https://clinicaltrials.gov/show/NCT00000194", "Gender": "Male", "FileName": "NCT00000194.txt", "NCTID": "NCT00000194", "Summary": "The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.", "OrgStudyId": "NIDA-00191-3", "Keywords": "['opioid disorders']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000194.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Neurobiology of Opioid Dependence: 3", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1993", "Title": "Neurobiology of Opioid Dependence: 4 - 4", "URL": "https://clinicaltrials.gov/show/NCT00000195", "Gender": "Both", "FileName": "NCT00000195.txt", "NCTID": "NCT00000195", "Summary": "The purpose of this study is to determine the effect of chronic naltrexone pre-treatment on the response to yohimbine in healthy volunteers.", "OrgStudyId": "NIDA-00191-4", "Keywords": "['opioid disorders']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000195.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Neurobiology of Opioid Dependence: 4", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1993", "Title": "Neurobiology of Opioid Dependence: 5 - 5", "URL": "https://clinicaltrials.gov/show/NCT00000196", "Gender": "Both", "FileName": "NCT00000196.txt", "NCTID": "NCT00000196", "Summary": "The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.", "OrgStudyId": "NIDA-00191-5", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000196.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Neurobiology of Opioid Dependence: 5", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "January 1987", "Title": "Propranolol for Treatment of Cocaine Addiction - 2", "URL": "https://clinicaltrials.gov/show/NCT00000197", "Gender": "Both", "FileName": "NCT00000197.txt", "NCTID": "NCT00000197", "Summary": "The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.", "OrgStudyId": "NIDA-00238-2", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000197.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Propranolol for Treatment of Cocaine Addiction", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "49", "MinimumAge": "25"},
{"StartDate": "October 1996", "Title": "Piracetam for Treatment of Cocaine Addiction - 3", "URL": "https://clinicaltrials.gov/show/NCT00000198", "Gender": "Male", "FileName": "NCT00000198.txt", "NCTID": "NCT00000198", "Summary": "The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program.", "OrgStudyId": "NIDA-00238-3", "Keywords": "['cocaine']", "Phase": "Phase 1", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000198.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Piracetam for Treatment of Cocaine Addiction", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "45", "MinimumAge": "21"},
{"MaximumAge": "0", "Title": "Piracetam for Treatment of Cocaine Addiction, Phase II - 4", "URL": "https://clinicaltrials.gov/show/NCT00000199", "Gender": "Both", "FileName": "NCT00000199.txt", "NCTID": "NCT00000199", "Summary": "The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.", "OrgStudyId": "NIDA-00238-4", "Keywords": "['cocaine']", "Phase": "Phase 1", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000199.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Piracetam for Treatment of Cocaine Addiction, Phase II", "HealthyVolunteers": "No", "OverallStatus": "Withdrawn", "MinimumAge": "0"},
{"StartDate": "January 1997", "Title": "Cocaine Effects in Humans: Physiology and Behavior - 1", "URL": "https://clinicaltrials.gov/show/NCT00000200", "Gender": "Both", "FileName": "NCT00000200.txt", "NCTID": "NCT00000200", "Summary": "The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.", "OrgStudyId": "NIDA-03818-1", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000200.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Cocaine Effects in Humans: Physiology and Behavior", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "45", "MinimumAge": "18"},
{"MaximumAge": "0", "Title": "Pharmacological Modulation of Cocaine Effects - 1", "URL": "https://clinicaltrials.gov/show/NCT00000201", "Gender": "Female", "FileName": "NCT00000201.txt", "NCTID": "NCT00000201", "Summary": "The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.", "OrgStudyId": "NIDA-05196-1", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000201.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Pharmacological Modulation of Cocaine Effects", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MinimumAge": "0"},
{"StartDate": "August 1988", "Title": "Buprenorphine Maintenance for Opioid Addicts - 1", "URL": "https://clinicaltrials.gov/show/NCT00000202", "Gender": "Both", "FileName": "NCT00000202.txt", "NCTID": "NCT00000202", "Summary": "The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.", "OrgStudyId": "NIDA-05626-1", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000202.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Buprenorphine Maintenance for Opioid Addicts", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "65", "MinimumAge": "18"},
{"StartDate": "August 1988", "Title": "Buprenorphine Maintenance for Opioid Addicts - 2", "URL": "https://clinicaltrials.gov/show/NCT00000203", "Gender": "Both", "FileName": "NCT00000203.txt", "NCTID": "NCT00000203", "Summary": "The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.", "OrgStudyId": "NIDA-05626-2", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000203.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Buprenorphine Maintenance for Opioid Addicts", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "August 1988", "Title": "Buprenorphine Maintenance for Opioid Addicts - 3", "URL": "https://clinicaltrials.gov/show/NCT00000204", "Gender": "Both", "FileName": "NCT00000204.txt", "NCTID": "NCT00000204", "Summary": "The purpose of this study is to evaluate buprenorphine in a medical maintenance model three times a week.", "OrgStudyId": "NIDA-05626-3", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000204.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Buprenorphine Maintenance for Opioid Addicts", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "0", "MinimumAge": "0"},
{"StartDate": "October 1990", "Title": "Buprenorphine Maintenance Protocol - 1", "URL": "https://clinicaltrials.gov/show/NCT00000205", "Gender": "Both", "FileName": "NCT00000205.txt", "NCTID": "NCT00000205", "Summary": "The purpose of this study is to compare the efficacy of buprenorphine versus methadone.", "OrgStudyId": "NIDA-06082-1", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000205.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Buprenorphine Maintenance Protocol", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "50", "MinimumAge": "21"},
{"StartDate": "April 1991", "Title": "Clinical Rescue Protocol - 2", "URL": "https://clinicaltrials.gov/show/NCT00000206", "Gender": "Both", "FileName": "NCT00000206.txt", "NCTID": "NCT00000206", "Summary": "The purpose of this study is to detect increasing medication dose results in heroin cessation for patients still using, to determine if decreasing medication dose in patients unable to tolerate medication dose increases retention, and to determine if blood levels of methadone or buprenorphine correlate with clinical response.", "OrgStudyId": "NIDA-06082-2", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000206.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Clinical Rescue Protocol", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "50", "MinimumAge": "21"},
{"StartDate": "May 1992", "Description": "12 different sites for a total of 736 subjects (60 at Pizarro, 70 at West LA Tx center, 15 in the 1 year extension)", "Title": "Multicenter Clinical Trial of Buprenorphine - 3", "URL": "https://clinicaltrials.gov/show/NCT00000207", "Gender": "Both", "FileName": "NCT00000207.txt", "NCTID": "NCT00000207", "Summary": "The purpose of this study is to test the efficacy and safety of buprenorphine.", "OrgStudyId": "NIDA-06082-3", "Keywords": "['Buprenorphine','Opioid']", "Phase": "Phase 3", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000207.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Multicenter Clinical Trial of Buprenorphine", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "50", "MinimumAge": "21"},
{"StartDate": "February 1992", "Title": "Methadone/Buprenorphine Cross-Over Study - 4", "URL": "https://clinicaltrials.gov/show/NCT00000208", "Gender": "Both", "FileName": "NCT00000208.txt", "NCTID": "NCT00000208", "Summary": "The purpose of this study is to explore ways to cross patients over from methadone to buprenorphine.", "OrgStudyId": "NIDA-06082-4", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000208.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Methadone/Buprenorphine Cross-Over Study", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "50", "MinimumAge": "21"},
{"StartDate": "November 1992", "Title": "Buprenorphine Dosing Interval - 5", "URL": "https://clinicaltrials.gov/show/NCT00000209", "Gender": "Both", "FileName": "NCT00000209.txt", "NCTID": "NCT00000209", "Summary": "The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.", "OrgStudyId": "NIDA-06082-5", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000209.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Buprenorphine Dosing Interval", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "50", "MinimumAge": "21"},
{"MaximumAge": "41", "Title": "Treatment Efficacy for Drug Abuse and AIDS Prevention - 1", "URL": "https://clinicaltrials.gov/show/NCT00000210", "Gender": "Male", "FileName": "NCT00000210.txt", "NCTID": "NCT00000210", "Summary": "The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.", "OrgStudyId": "NIDA-06116-1", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000210.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Treatment Efficacy for Drug Abuse and AIDS Prevention", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MinimumAge": "26"},
{"MaximumAge": "41", "Title": "Treatment Efficacy for Drug Abuse and AIDS Prevention - 2", "URL": "https://clinicaltrials.gov/show/NCT00000211", "Gender": "Male", "FileName": "NCT00000211.txt", "NCTID": "NCT00000211", "Summary": "The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.", "OrgStudyId": "NIDA-06116-2", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000211.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "Treatment Efficacy for Drug Abuse and AIDS Prevention", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MinimumAge": "26"},
{"StartDate": "July 1987", "Title": "IV Cocaine Abuse: A Laboratory Model - 1", "URL": "https://clinicaltrials.gov/show/NCT00000212", "Gender": "Both", "FileName": "NCT00000212.txt", "NCTID": "NCT00000212", "Summary": "The purpose of this study is to evaluate the effects of desipramine DMI maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.", "OrgStudyId": "NIDA-06234-1", "Keywords": "['crack cocaine']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000212.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "IV Cocaine Abuse: A Laboratory Model", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "45", "MinimumAge": "18"},
{"StartDate": "April 1990", "Title": "IV Cocaine Abuse: A Laboratory Model - 2", "URL": "https://clinicaltrials.gov/show/NCT00000213", "Gender": "Both", "FileName": "NCT00000213.txt", "NCTID": "NCT00000213", "Summary": "The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.", "OrgStudyId": "NIDA-06234-2", "Keywords": "['intravenous abuse']", "Phase": "Phase 2", "MyURL": "https://azure.storagedemos.com/clinical-trials/NCT00000213.txt", "Date": "ClinicalTrials.gov processed this data on October 25, 2016", "OfficialTitle": "IV Cocaine Abuse: A Laboratory Model", "HealthyVolunteers": "No", "OverallStatus": "Completed", "MaximumAge": "45", "MinimumAge": "18"}]
